Close Menu

Invitae

Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

Invitae estimated that in 2020 it would accession more than 725,000 samples and bring in more than $330 million in revenue, slightly above current Wall Street projections.

In seven years, the public variant classification database has steadily become a resource that labs are submitting to and that genetics experts are consulting.

The GenomeWeb Index vastly outperformed the Dow Jones and the Nasdaq Biotechnology Index this month, while slightly underperforming the Nasdaq.

Amid rapid adoption of multi-gene panels, ACMG experts are seeing some doctors and patients taking actions they shouldn't.

Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.

The GenomeWeb Index outperformed the Dow Jones and the Nasdaq, but underperformed the Nasdaq Biotechnology Index this month.

News items for the week of Nov. 11.

The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.

Pages

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.